Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||EW0151 / 1||LA / OT|
Administered by: Pharmacy Purchased by: ??
Symptoms: Chest pain, Troponin increased, Troponin, SARS-CoV-2 test
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? Yes
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? Yes
Hospitalized? Yes, days: 4
Write-up: Acute chest pain; Elevated troponin 16; This is spontaneous report received from a contactable Healthcare professional. A 17-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) intramuscularly on 08Apr2021 13:15 (Batch/Lot Number: EW0151) (at 17-year-old) as first dose, single in arm left for COVID-19 immunisation. Other unspecified Pfizer vaccine was received via an unspecified route of administration on 08Apr2021 (Batch/Lot Number: EW0170) as second dose, single in arm. Medical history included ongoing hospitalization (Vaccine received during existing hospitalization). The patient''s other concomitant medications were not reported. No other vaccines within 4 weeks prior to the COVID vaccine. Other medications received within 2 weeks of vaccination was reported as unknown. On 02May2021 04:00 AM, the patient experienced acute chest pain and elevated troponin 16, he was admitted to hospital. It''s reported AE resulted in: Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Prolongation of existing hospitalization (vaccine received during existing hospitalization). Prior to vaccination, the patient was not diagnosed with COVID-19. On 02May2021, PCR Nasal Swab was performed and showed negative. Ketorolac tromethamine (TORADOL) and ibuprofen (MOTRIN) were received as treatment. Duration of hospitalization was 4 (discharged on 06May2021). The outcome of the event was resolved in May2021.; Sender''s Comments: Based on the strong temporal relation, the association between chest pan, troponin increased and vaccine administration cannot be completely ruled out with the information available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166